Live updates: FDA Advisory Committee on talazoparib plus enzalutamide for mCRPC
FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk
Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer
Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC